• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 8:00:58 AM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLDO alert in real time by email
    SC 13G 1 d18399dsc13g.htm SCHEDULE 13G Schedule 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

     

    Kaleido Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    483347100

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 483347100

     

      1      

    NAMES OF REPORTING PERSONS

     

    HarbourVest Partners L.P.

      2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐         (b)  ☐

     

      3   

    SEC USE ONLY

     

      4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5       

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,833,832

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,833,832

      9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,833,832

      10    

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

      11 

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1%

      12 

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

    2 of 10


    CUSIP No. 483347100

     

      1      

    NAMES OF REPORTING PERSONS

     

    HarbourVest Partners, LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐         (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5       

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,833,832

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,833,832

      9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,833,832

      10    

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

      11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1%

      12

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

    3 of 10


    CUSIP No. 483347100

     

      1      

    NAMES OF REPORTING PERSONS

     

    SMRS-TOPE LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐         (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5       

    SOLE VOTING POWER

     

    1,833,832

       6   

    SHARED VOTING POWER

     

    0

       7   

    SOLE DISPOSITIVE POWER

     

    1,833,832

       8   

    SHARED DISPOSITIVE POWER

     

    0

      9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,833,832

      10    

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

      11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1%

      12

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    4 of 10


    CUSIP No. 483347100

     

      1      

    NAMES OF REPORTING PERSONS

     

    HVST-TOPE LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a)  ☐         (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5       

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,833,832

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,833,832

      9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,833,832

      10    

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

      11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1%

      12

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    5 of 10


    CUSIP No. 483347100

     

    Item 1.

     

      (a)

    Name of Issuer:

    Evelo Biosciences, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    65 Hayden Avenue

    Lexington, MA 02421

    (617) 674-9000

    Item 2.

     

      (a)

    Name of Person Filing:

    HarbourVest Partners, LLC

    HarbourVest Partners L.P.

    HVST-TOPE LLC

    SMRS-TOPE LLC

    SMRS-TOPE LLC, HVST-TOPE LLC, HarbourVest Partners L.P. and HarbourVest Partners, LLC have entered into a Joint Filing Agreement, dated February 16, 2021, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which such reporting persons have agreed to file this statement and any amendments thereto jointly in accordance with the provisions of 13d-1(k)(1) under the Securities Exchange Act of 1934.

     

      (b)

    Address of Principal Business Office or, if none, Residence

    The principal business office of each reporting person is One Financial Center, Boston, MA 0211.

     

      (c)

    Citizenship:

    Reporting entities are all organized and exist under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

    Common stock, par value $0.001 per share

     

      (e)

    CUSIP Number:

    483347100

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    6 of 10


    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned:

    Consists of 1,833,832 shares of common stock owned directly by SMRS-TOPE LLC. HarbourVest Partners, LLC (“HarbourVest”) is the General Partner of HarbourVest Partners L.P., which is the Manager of HVST-TOPE LLC, which is the Managing Member of SMRS-TOPE LLC. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have a beneficial interest in the shares held by SMRS-TOPE LLC.

    Voting and investment power over the securities owned directly by SMRS-TOPE LLC is exercised by the Investment Committee of HarbourVest. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC and the members of the HarbourVest Investment Committee disclaim beneficial ownership of the shares held directly by SMRS-TOPE LLC.

     

    (b)

    Percent of class:

    5.1% (based on the Issuer’s aggregate of 35,982,105 shares of common stock outstanding as of October 30, 2020, as reported in the Issuer’s Form 10-Q, filed with the SEC on November 2, 2020).

     

    (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote:

    SMRS-TOPE LLC has the sole power to vote or to direct the vote of 1,833,832 shares of common stock.

     

    7 of 10


    (ii) Shared power to vote or to direct the vote:

    HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared power to vote or direct the vote of 1,833,832 shares of common stock. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC disclaim such beneficial ownership of such shares.

    (iii) Sole power to dispose or to direct the disposition:

    SMRS-TOPE LLC has the sole power to dispose or to direct the disposition of 1,833,832 shares of common stock.

    (iv) Shared power to dispose or to direct the disposition:

    HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared power to dispose or direct the disposition of 1,833,832 shares of common stock. Each of HarbourVest, HarbourVest Partners L.P. and HVST-TOPE LLC disclaim such beneficial ownership of such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]:

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    See item 4 above.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.

     

    8 of 10


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    HARBOURVEST PARTNERS, LLC
    By:   /s/ William Royer
    Name:  

    William Royer

    Title:   Chief Compliance Officer
    HARBOURVEST PARTNERS L.P.
    By:   HarbourVest Partners, LLC, its General Partner
    By:   /s/ William Royer
    Name:  

    William Royer

    Title:   Chief Compliance Officer
    HVST-TOPE LLC
    By:   HarbourVest Partners L.P., its Manager
    By:   HarbourVest Partners, LLC, its General Partner
    By:   /s/ William Royer
    Name:  

    William Royer

    Title:   Chief Compliance Officer
    SMRS-TOPE LLC
    By:   HVST-TOPE LLC, its Managing Member
    By:   HarbourVest Partners L.P., its Manager
    By:   HarbourVest Partners, LLC, its General Partner
    By:   /s/ William Royer
    Name:  

    William Royer

    Title:   Chief Compliance Officer

     

    9 of 10

    Get the next $KLDO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KLDO

    DatePrice TargetRatingAnalyst
    1/31/2022$11.00 → $3.00Buy
    Chardan Capital
    11/12/2021$15.00 → $11.00Buy
    Chardan Capital
    11/3/2021$25.00 → $22.00Market Outperform
    JMP Securities
    10/19/2021$3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $KLDO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Van Hylckama Vlieg Johan covered exercise/tax liability with 2,087 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,620 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:09:49 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Korn Jerald covered exercise/tax liability with 2,046 units of Restricted Stock Units, decreasing direct ownership by 31% to 4,517 units

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      3/2/22 4:05:37 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Van Hylckama Vlieg Johan

      4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)

      1/18/22 5:18:21 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously

      1/31/22 9:22:16 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on Kaleido Biosciences with a new price target

      Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously

      11/12/21 7:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities reiterated coverage on Kaleido Biosciences with a new price target

      JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously

      11/3/21 7:54:29 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kaleido Biosciences Inc.

      15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)

      5/6/22 8:15:52 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Kaleido Biosciences Inc.

      EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)

      5/2/22 12:15:14 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Kaleido Biosciences Inc.

      S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)

      4/25/22 4:42:53 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology

      CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.

      1/26/22 9:31:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations

    $KLDO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Radius Health Announces Leadership Appointments

      BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company's Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in publicly listed companies. His experience includes all aspects of finance including business unit accounting, regulatory, corporate books and records, budget processes, internal & external audit a

      3/16/22 8:30:00 AM ET
      $KLDO
      $RDUS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Specialties
      Consumer Discretionary
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations

    $KLDO
    Financials

    Live finance-specific insights

    See more
    • Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

      KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at end of study Virtual R&D Presentation, highlighting the ulcerative colitis and chronic obstructive pulmonary disease programs, to be held today at 8:00 a.m. ET LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore g

      10/5/21 7:00:00 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

      Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 studies LEXINGTON, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET. The agenda will feature an update on the Company's corporate strategy, data from the non-IND stu

      9/29/21 7:30:00 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

      For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

      9/7/21 4:11:11 PM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLDO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kaleido Biosciences Inc. (Amendment)

      SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)

      5/10/22 10:13:04 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kaleido Biosciences Inc. (Amendment)

      SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)

      2/9/22 9:22:49 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Kaleido Biosciences, Inc. (0001751299) (Subject)

      2/16/21 8:00:58 AM ET
      $KLDO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care